CFR Chemaphor Inc.

Chemaphor Inc. (TSX VENTURE:CFR) and its subsidiary Avivagen Animal Health Inc,
today announced that Avivagen Animal Health has officially launched its
commercial operations this week. Avivagen has begun marketing exclusively
through the veterinary channel in Canada its proprietary Oximunol(TM) Chewable
Tablets for dogs and its in-licensed VetStem RC regenerative cell treatment for
dogs, horses and cats.


Dave Hankinson, CEO of Chemaphor and Avivagen commented that "it is gratifying
that Chemaphor, through Avivagen, is now able to enter the market with its first
commercial products, which have come to fruition after much effort expended on
both the research and development and the business development fronts. Our sales
representatives are finding considerable interest and excitement across Canada
among the veterinarians they visit, for both the VetStem RC regenerative cell
treatment and Oximunol(TM) Chewable Tablets. Indeed, I am pleased to say that
the first orders already have been received by Avivagen, and that delivery is
slated to begin shortly."


At the same time, Chemaphor has launched a dedicated, interactive website in
support of Avivagen's products and services (www.avivagen.com). Dave Hankinson
remarked that "we believe it is important to take full advantage of the social
media capabilities of online communities, to communicate with and build the
all-important, long-term relationships with pet parents and veterinarians. At
the same time this discussion creates awareness of and buying interest in our
novel and innovative products and services. Accordingly, we have appointed a
dedicated consumer and marketing communications coordinator, Jennifer Febel, who
will be blogging on the website and facilitating discussion with website
visitors through services such as Facebook and Twitter, as well as by regular
email. Veterinarians who would like to discuss aspects of our products and
services, can contact Dr. Isabelle Epshtein-Verzberger, our veterinary research
scientist, whose responsibilities include leading the canine clinical trials
program. Questions of a general nature can be directed to the appropriate
individual though the Avivagen customer service support desk."


For further information please direct enquiries to any of the appropriate
resources listed below.


About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering
products to humans and animals to assist in optimizing health and daily quality
of life. Chemaphor is advancing product candidates for the food animal market,
companion animal market and various, potential human applications. More
information can be found at www.chemaphor.com. 


Forward Looking Statements

This news release includes certain forward-looking statements that are based
upon current expectations, which involve risks and uncertainties associated with
Chemaphor's business and the environment in which the business operates. Any
statements contained herein that are not statements of historical facts may be
deemed to be forward-looking, including those identified by the expressions
"anticipate", "believe", "plan", "estimate", "expect", "intend", and similar
expressions to the extent they relate to Chemaphor or its management. The
forward-looking statements are not historical facts, but reflect Chemaphor's
current expectations regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that could cause
actual results or events to differ materially from current expectations.
Chemaphor assumes no obligation to update the forward-looking statements, or to
update the reasons why actual results could differ from those reflected in the
forward-looking statements.

Chemaphor Inc. (TSXV:CFR)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

Chemaphor Inc. (TSXV:CFR)
Historical Stock Chart
Von Jul 2023 bis Jul 2024